•   
  •   
  •   

Politics Centrists throw wrench in House Democrats’ drug pricing plans

23:25  14 september  2021
23:25  14 september  2021 Source:   politico.com

Daily on Energy: Schumer betting on huge emissions cuts from infrastructure package

  Daily on Energy: Schumer betting on huge emissions cuts from infrastructure package Subscribe today to the Washington Examiner magazine and get Washington Briefing: politics and policy stories that will keep you up to date with what's going on in Washington. SUBSCRIBE NOW: Just $1.00 an issue! © Provided by Washington Examiner DOE Default Image - July 2021 EMISSIONS CUTS FROM DEMOCRATIC LEGISLATION: Senate Majority Leader Chuck Schumer says Democrats’ climate and infrastructure plans being pursued this fall have the potential to nearly fulfill President Joe Biden’s Paris Agreement pledge to cut U.S. emissions in half by 2030.

An intraparty fight over drug price controls is threatening to derail Democrats' dreams of sweeping changes to Medicare, Medicaid and the Affordable Care Act as part of their mammoth social spending package.

Nydia Velazquez, Scott Peters sitting in a suit and tie: Rep. Scott Peters speaks at the Capitol in Washington, Wednesday, Dec. 18, 2019. © House Television via AP Rep. Scott Peters speaks at the Capitol in Washington, Wednesday, Dec. 18, 2019.

House Energy and Commerce Chair Frank Pallone (D-N.J.) and his senior aides are racing to shore up support for leadership-backed language that would allow direct government negotiations over the prices of hundreds of drugs, penalize manufacturers that raise prices faster than inflation and apply both policies to private insurance plans as well as Medicare.

3 Key Divides in Democrats’ Civil War Over the Biden Agenda

  3 Key Divides in Democrats’ Civil War Over the Biden Agenda It’s not just progressives versus moderates.Joe Biden may have less room for error.

Efforts to wrap the language into the House Democrats' party-line social spending bill ran into opposition Tuesday from a cadre of moderates led by Rep. Scott Peters (D-Calif.), who put forward a narrower set of pricing policies and threatened to withhold their support unless they're adopted. The centrist group, which also includes Reps. Kathleen Rice (D-N.Y.) and Kurt Schrader (D-Ore.), would only allow negotiation for a small subset of drugs in Medicare Part B that have no competition.

“I support many of the proposals being considered this week, but I do not support advancing policies that are not fiscally responsible and jeopardize the bill’s final passage,” Rice said.

The standoff came as the Energy and Commerce panel marked up its portion of the giant package set for passage using the filibuster-proof budget reconciliation process. And the clash's result could determine if Democrats can spend as much as $700 billion in projected savings over a decade on other health policy priorities, like adding dental, vision and hearing benefits to Medicare, making enhanced Affordable Care Act subsidies permanent and offering Medicaid coverage to 2 million people in red states that have refused to expand the program.

Moderate House Democrats threaten drug pricing bill in House panel

  Moderate House Democrats threaten drug pricing bill in House panel Three moderate House Democrats announced that they would vote against their party's legislation to lower drug prices in committee on Tuesday, threatening a defeat for one of Democrats' signature measures. Reps. Kurt Schrader (D-Ore.), Scott Peters (D-Calif.) and Kathleen Rice (D-N.Y.) announced in separate statements on Tuesday that they would vote against the section of Democrats' $3.5 trillion package dealing with lowering drug prices during a markup in the House Energy and Commerce Committee, which is currently ongoing.

But the Peters-led plan is a non-starter for progressives, who argue that it lets the drug industry off easy and would generate far less savings to apply to other health priorities.

As Speaker Nancy Pelosi’s members tussle, the uncertainty over drug pricing complicates her team's timeline for moving the social spending package through the House this month. Individual committees are supposed to report their portions to the House Budget Committee by Wednesday so the panel can begin assembling the legislation for floor action later this month.

Should Peters, Rice and Schrader join all the panel's Republicans in voting against the drug pricing section of the bill, preventing it from advancing out of committee, it would mark an embarrassment for leadership, after Democrats from President Joe Biden to Senate Budget Chair Bernie Sanders (I-Vt.) spent months vowing to lower out-of-pocket health spending for tens of millions, if not hundreds of millions, of people. Democrats noted, however, that if all else fails they could add the provisions back later in the process, when the committee’s whole package goes before the Budget Committee.

Overnight Health Care — Democrats face setback on drug pricing

  Overnight Health Care — Democrats face setback on drug pricing Welcome to Wednesday's Overnight Health Care, where we're following the latest moves on policy and news affecting your health. Subscribe here: thehill.com/newsletter-signup.It's been over a week, and the zebras running loose in Maryland-which were definitely not freed by Eleanor Holmes Norton- are still out there. Be safe! Three Democrats in the House voted against a drug pricing amendment, throwing the party's signature plan to lower the cost of prescription drugs into question. For The Hill, we're Peter Sullivan (psullivan@thehill.com), Nathaniel Weixel (nweixel@thehill.com) and Justine Coleman (jcoleman@thehill.com).

An Energy and Commerce Committee spokesperson said that efforts on the bill are “ongoing” and Pallone “continues to work to favorably report out all of the Committee’s reconciliation legislative recommendations.”

Still, many Democrats are worried.

Schrader has already signaled that he’s likely to vote against the committee’s bill. Democrats are still trying to win over Peters and Rice, who have privately threatened to oppose just the drug pricing portion of the legislation.

“It’s not looking good,” an aide to one Democrat on the committee told POLITICO, predicting that the whole drug pricing section of the bill won’t be able to advance. “As it stands with votes, it looks like the window on this is closing.”

The centrists’ revolt also sparked a panic with progressive advocacy groups like the Center for Popular Democracy, who on Tuesday blasted out alerts urging their members to call members of Congress and press them to vote for the more aggressive drug pricing bill.

The dispute over how aggressive the government should be in bargaining down drug prices will likely decide other ongoing Democratic fights over how to divvy up funding between Medicare, Medicaid and Obamacare. That's because the drug price savings effectively lay out just how much spare spending lawmakers will have to work with.

K Street counting on Senate to pare back Democrats’ tax plan

  K Street counting on Senate to pare back Democrats’ tax plan Lobbyists for business interests are confident they can fight off parts of House tax proposal they find most threatening.In interviews this week, lobbyists representing a range of business interests said they aren’t too worried about the party’s opening salvo on tax increases, confident the bill — and the threats their clients insist it poses — will be pared back in order to thread its way through a narrowly divided House and Senate.

“There’s an independent reason to succeed on drug price negotiations, and that is that we’re often paying three times what everyone else in the world is paying for drugs,” said Rep. Peter Welch (D-Vt.), who sits on the committee and is among those leading the push for Medicare negotiation. “But only if we succeed can we have a debate about how to use those savings.”

With pressure on Democrats to raise enough revenue to fund major expansions of other health programs, the bill will save an estimated $700 billion over ten years, compared to the $492 billion saved by the previous version, according to the Joint Committee on Taxation.

The moderate dissenters argue that the leadership-backed drug pricing language is going nowhere in the Senate — and that Democrats shouldn’t be subjected to what could be a tough political vote for no reason.

Two more moderate Democrats, Reps. Lou Correa and Stephanie Murphy, have cosponsored Peters’ alternative drug bill, signaling potential problems for a future floor vote, since the party can only lose three votes and still pass the overall package.

Meanwhile, Senate moderates are trying to slash the size of the overall bill. The full Democratic caucus took a “temperature check” on the issue at its weekly lunch on Tuesday but did not reach a final consensus, an aide said in an interview, addressing the question on condition of anonymity. Sen. Ron Wyden (D-Ore.), who is leading the drug pricing effort in the upper chamber, told reporters he is still looking at “various approaches” that include direct government negotiation “while being sensitive to innovation.”

Sinema tells White House she’s opposed to current prescription drug plan

  Sinema tells White House she’s opposed to current prescription drug plan During meetings last week, the Arizona Democrat joined Joe Manchin in giving the president what was described as a wake-up call on the reconciliation bill.The Arizona Democrat is opposed to the current prescription drug pricing proposals in both the House and Senate bills, two sources familiar with her thinking said. They added that, at this point, she also doesn’t support a pared-back alternative being pitched by House Democratic centrists that would limit the drugs subject to Medicare negotiation.

One sticking point is that the House leadership drug pricing plan would peg drug prices negotiated in the U.S. to what's paid in countries that use a metric called Quality-Adjusted Life Years to determine a drug’s value. This measure of health outcomes and quality of life has been criticized for discriminating against people with disabilities.

Many House Democrats have said they don’t want to take tough votes on anything that won’t be able to pass the Senate. Yet getting rid of the international benchmarking alone would threaten the overall effort, a source close to the Energy and Commerce Committee explained, because hundreds of billions in savings come from just that one provision.

Besides their own internal divisions, Democrats will have to overcome stiff opposition from powerful health industry lobbies in order to get a bill across the finish line. Key groups have spent years arguing over how many drugs should be subject to government bargaining rules, what benchmark the prices will be pegged to, and whether the lower prices will apply to employer plans and other private insurance, and are currently pouring resources into ads and lobbying aimed at blocking the bill’s passage.

Welch and others pushing for a sweeping negotiation bill attribute the moderates’ revolt to the industry’s lobbying blitz and donations to Peters, Schrader and others opposed to the legislation.

“There is angst,” he said of Democrats’ current drug pricing fight. “But the angst is from the pharmaceutical industry that we’re actually going to lower the cost of prescription drugs, and that gets translated into arguments that are propped up to stop us from proceeding.”

Until the party can find common ground on a drug bill that satisfies both moderates’ and progressives’ concerns, all of the party’s other health policy fights remain up in the air.

“The general dynamic is that things are still fluid,” a senior Democratic aide said in an interview. “It depends how much money can be raised.”

Five Reasons Why Infrastructure Is Dead—And One Why It’s Not .
This article is part of the The DC Brief, TIME’s politics newsletter. Sign up here to get stories like this sent to your inbox every…Remember the good ol’ days of 2019, before COVID-19 changed almost everything? Back when Joe Biden was the affable former Vice President who promised to bring people together? When his advisers insisted time and again that his 36 years in the Senate and eight years as Barack Obama’s Congress Whisperer would get big deals across the finish line? Well, Washington is waiting to see if he can actually deliver on that sale, and it’s looking dicey.

usr: 1
This is interesting!